Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xencor, CSL Enter Antibody Optimization Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Xencor, CSL Enter Antibody Optimization Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Xencor, Inc. has entered into an antibody optimization collaboration with CSL, Ltd., under which CSL will have access to Xencor’s XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

Xencor has granted CSL several commercial licenses to move product candidates into development and commercialization that use Xencor’s XmAb technology. In addition to an undisclosed upfront payment, Xencor will receive development milestone payments and product royalties for each product commercialized using the Xencor technology.

“We are excited to collaborate with our CSL colleagues and enable their antibody products through the use of our XmAb technology,” commented Bassil Dahiyat, Ph.D., Xencor’s chief executive officer.

“We are pleased that the market is recognizing the preferred development friendly solution to increasing antibody effector function that Xencor offers,” commented James Posada, Ph.D., MBA, Xencor’s acting chief business officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters